trending Market Intelligence /marketintelligence/en/news-insights/trending/7fvkblfcjxzyjagueigt5g2 content esgSubNav
In This List

BioSig Technologies seeks US FDA approval for cardiac recording system

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


BioSig Technologies seeks US FDA approval for cardiac recording system

BioSig Technologies Inc. filed a 510(k) application with the U.S. Food and Drug Administration for its PURE EP System.

The Los Angeles-based medical device company is seeking approval for the surface electrocardiogram and intracardiac multichannel recording system, which aims to produce high-fidelity heart recordings during electrophysiology studies and catheter ablation procedures.

Catheter ablation is a procedure to treat atrial fibrillation, the most common form of quivering or irregular heartbeat known as arrhythmia. Atrial fibrillation affects 6.1 million people in the U.S., increasing their risk of stroke by 4 to 5 times.

BioSig Technologies said it has conducted 11 pre-clinical studies and one clinical trial between 2015 and 2018.